Inclisiran is a first-in-class injectable medicine that lowers LDL cholesterol ("bad" cholesterol) using a gene-silencing technology called siRNA (small interfering RNA). It belongs to a class of medicines that target PCSK9, mainly used alongside diet, exercise, and often statin therapy to further reduce LDL cholesterol. It is a prescription-only, healthcare-provider-administered medicine.

• Therapeutic Class: Lipid-lowering (anti-hyperlipidemic) medicine.

• Pharmacological Class: PCSK9 (proprotein convertase subtilisin/kexin type 9) synthesis inhibitor.

• Drug Family: Small interfering RNA (siRNA) therapeutics.

• ATC Classification: C10AX16 (Inclisiran).

Approved: As an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), either as monotherapy or alongside statin therapy; also used in adults with clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering.

Commonly used for: Patients who haven't reached their LDL cholesterol target on statins alone, or who need an alternative/additional option due to statin intolerance, difficulty with daily pill adherence, or inherited high cholesterol.

Off-label use (only under medical guidance): Not typically used off-label, given its defined lipid-lowering indication.

●       Injection (subcutaneous, prefilled syringe): 284 mg/1.5 mL single-dose syringe.

Inclisiran uses RNA interference technology to target the messenger RNA (mRNA) that the liver uses to produce a protein called PCSK9. PCSK9 normally breaks down LDL receptors on liver cells, reducing the liver's ability to clear LDL cholesterol from the blood. By silencing PCSK9 production, inclisiran allows more LDL receptors to remain active on liver cells, increasing LDL cholesterol uptake and clearance from the bloodstream.

• Standard dose: 284 mg (one prefilled syringe) given as a subcutaneous injection, followed by a second dose at 3 months, then a maintenance dose every 6 months thereafter.

• Condition-wise dose: The same twice-yearly maintenance schedule applies whether used as monotherapy or alongside statin therapy; no separate dose adjustment by indication.

• Route: Subcutaneous injection, administered by a healthcare provider (not self-injected) in the abdomen, upper arm, or thigh.

• Missed dose: If a scheduled dose is delayed by more than 3 months from its planned date, the dosing schedule is restarted with a new initial dose, followed by a dose at 3 months, then every 6 months — as directed by the treating clinician.

• Overdose: Not established beyond recommended dosing; managed by the treating clinical team if it occurs.

• Common: Injection-site reactions (pain, redness, rash), joint pain, and symptoms of a cold (upper respiratory infection).

• Serious: Serious allergic reactions, though uncommon.

• Emergency symptoms: Difficulty breathing or swallowing, swelling of the face/lips/tongue/throat, dizziness or feeling faint, a drop in blood pressure, or severe skin itching with a red rash or raised bumps.

• Recovery advice: Injection-site reactions are usually mild and temporary, typically resolving within a few days without specific treatment.

Pregnancy: Used only if clearly needed, as safety data in pregnancy are limited.

Breastfeeding: Discussed with the treating doctor given limited safety data.

Liver disease: Used with caution; specific dose adjustment has not been extensively established for severe impairment.

Kidney disease: No specific dose adjustment required across a range of kidney function, including severe impairment, based on available data.

Elderly: Commonly used in this age group, as high cholesterol and cardiovascular disease risk increase with age.

Children: Not established for use in children; an adult-only medicine.

●       Statins: inclisiran does not have significant pharmacokinetic interactions with statins and is commonly used alongside them.

●       Other lipid-lowering medicines (e.g., ezetimibe): generally used together without specific interaction concerns, as part of a broader cholesterol-lowering strategy.

●       No major CYP450-mediated drug interactions have been identified, as inclisiran is not metabolised through this enzyme system in the way many oral medicines are.

●       LDL cholesterol levels periodically to assess treatment response.

●       Full lipid panel as part of routine cardiovascular risk monitoring.

●       Observation for injection-site reactions or signs of an allergic reaction at the time of each administration.

Evolocumab, Alirocumab (other PCSK9-targeted therapies, given as monoclonal antibodies rather than siRNA, with more frequent dosing); statins and ezetimibe (oral options with different mechanisms).

Commonly used alongside maximally tolerated statin therapy for additional LDL-C lowering; also approved for use as monotherapy (without a statin) in adults with hypercholesterolemia, based on more recent label updates.

●       Cholesterol-Lowering Medicines

●       PCSK9-Targeted Therapies

●       Cardiovascular Risk Reduction Treatments

1. Six Best Foods To Lower Cholesterol

2. Reasons for Early Cardiovascular Disease in Young People in India

3. Rising cholesterol, obesity, metabolic issues among children in India

1. https://www.leqvio.com/

2. https://www.uspharmacist.com/article/fda-approves-twiceyearly-injectable-drug-to-lower-ldlc-levels

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.